Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shari Pilon-Thomas

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Cancer Cell|September 14, 2016
Tipping the Balancing ACTShari Pilon-Thomas, Brian Ruffell
Cellular Immunology|January 21, 2021
Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapyPatrick Innamarato, Shari Pilon-Thomas
Cancer Journal (Sudbury, Mass.)|July 26, 2022
Adoptive Cell Therapy for Advanced Solid TumorsJohn E Mullinax, Shari Pilon-Thomas
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanomaNobusada Koike, Shari Pilon-Thomas, James J Mulé
Frontiers in Immunology|June 26, 2025
Editorial: Artificial intelligence for cancer immunotherapyIssam El Naqa, Shari Pilon-Thomas, Eric Deutsch
Biorxiv : the Preprint Server for Biology|December 3, 2025
Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modelingNina Obertopp, Matthew Froid, Shari Pilon-Thomas, et al.
Neoplasia (New York, N.Y.)|April 21, 2022
Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune systemRebecca Anne Bekker, Sungjune Kim, Shari Pilon-Thomas, et al.
Frontiers in Immunology|June 15, 2026
Artificial intelligence for optimization of immunotherapy: current applications and transformative potentialAli Tarhini, Palak Dave, Shari Pilon-Thomas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 3, 2010
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaShari Pilon-Thomas, Amy Mackay, Nasreen Vohra, et al.
Cytotherapy|December 5, 2018
Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing processEmily L Hopewell, Cheryl Cox, Shari Pilon-Thomas, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Cancer Cell|September 14, 2016
Tipping the Balancing ACTShari Pilon-Thomas, Brian Ruffell
Cellular Immunology|January 21, 2021
Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapyPatrick Innamarato, Shari Pilon-Thomas
Cancer Journal (Sudbury, Mass.)|July 26, 2022
Adoptive Cell Therapy for Advanced Solid TumorsJohn E Mullinax, Shari Pilon-Thomas
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 9, 2008
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanomaNobusada Koike, Shari Pilon-Thomas, James J Mulé
Frontiers in Immunology|June 26, 2025
Editorial: Artificial intelligence for cancer immunotherapyIssam El Naqa, Shari Pilon-Thomas, Eric Deutsch
Biorxiv : the Preprint Server for Biology|December 3, 2025
Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modelingNina Obertopp, Matthew Froid, Shari Pilon-Thomas, et al.
Neoplasia (New York, N.Y.)|April 21, 2022
Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune systemRebecca Anne Bekker, Sungjune Kim, Shari Pilon-Thomas, et al.
Frontiers in Immunology|June 15, 2026
Artificial intelligence for optimization of immunotherapy: current applications and transformative potentialAli Tarhini, Palak Dave, Shari Pilon-Thomas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 3, 2010
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanomaShari Pilon-Thomas, Amy Mackay, Nasreen Vohra, et al.
Cytotherapy|December 5, 2018
Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing processEmily L Hopewell, Cheryl Cox, Shari Pilon-Thomas, et al.
Pageof 11